TG Therapeutics (TGTX) Misses Q2 EPS by 4c

TG Therapeutics (NASDAQ: TGTX) reported Q2 EPS of ($0.33), $0.04 worse than the analyst estimate of ($0.29). Revenue for the quarter came in at $30.1 thousand versus the consensus estimate of $40 thousand.

For earnings history and earnings-related data on TG Therapeutics (TGTX) click here.

You May Also Be Interested In

• After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
• ULTA Beauty (ULTA) PT Lowered to $710 at UBS Amid Gross Margin Decline
• Jiayin Group (JFIN) Reports Q2 Loss of RMB3.56